Marek's disease is an important lymphoproliferative neoplasm of chickens, caused by oncogenic strains of herpes virus. Visceral lymphomas and invasion of both central nervous tissues and peripheral nerves by lymphoid cells are common findings. Matrix metalloproteinases (MMPs) are a group of enzymes responsible for extracellular matrix degradation and tumour metastases. The localisations of MMPs in tumour cells were evaluated immunohistochemically. As a result, positive reactions for MMP-9 and MMP-2 enzymes were found in the lymphoid tumour cells. These enzymes may take part in the pathogenesis of Marek's disease causing extracellular matrix degradation and metastasis.
AbrahamM., ShapiroS., KarniA., WeinerH.L., and MillerA. (2005) Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J. Neuroimmunol., 163, 157–164.
2.
AimesR.T., FrenchD.L., and QuigleyJ.P. (1994) Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation. Biochem. J., 300, 729–736.
3.
AkkocA., KahramanM.M., CansecM., and OzyigitM.O. (2011) Effects of hypoxia and hyperosmosis on the expression of matrix metalloproteinases in boiler lung fibroblates. Avian Biol. Res., 4, 6–16.
4.
ArltM., KopitzC., PenningtonC., WatsonK.L., KrellH.W., BodeW., GansbacherB., KhokhaR., EdwardsD.R., and KrgerA. (2002) Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res., 1, 5543–5550.
5.
BarrowA.D., BurgessS.C., HowesK., and NairV.K. (2003) Monocytosis is associated with the onset of leukocyte and viral infiltration of the brain in chickens infected with the very virulent Marek's disease virus strain C12/130. Avian Pathol., 32, 183–191.
6.
BaigentS.J., SmithL.P., NairV.K., and CurrieR.J.W. (2006) Vaccinal control of Marek's disease: Current challenges, and future strategies to maximize protection. Vet. Immunol. Immunopathol., 112, 78–86.
7.
BjornlandK., FlatmarkK., PettersenS., AaasenA.O., FodstadO., and MaelandsmoG.M. (2005) Matrix metalloproteinases participate in osteosarcoma invasion. J. Surg. Res., 127, 151–156.
8.
BurgessS.C., YoungJ.R., BaatenB.J., HuntL., RossL.N., ParcellsM.S., KumarP.M., TregaskesC.A., LeeL.F., and DavisonT.F. (2004) Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30). Proc. Natl. Acad. Sci. USA, 21, 13879–13884.
Di GirolamoN., TedlaN., LloydA., and WakefieldD. (1998) Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur. J. Immunol., 28, 1773–1784.
11.
EgebladM., and WerbZ. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2, 161–174.
12.
EickelbergO., SommerfeldC.O., WyserC., TammM., ReichenbergerF., BardinP.G., SolerM., RothM., and PerruchoudA.P. (1997) MMP and TIMP expression pattern in pleural effusions of different origins. Am. J. Respir. Crit. Care Med., 156, 1987–1992.
13.
GimenoI.M., WitterR.L., HuntH.D., LeeL.F., ReddyS.M., and NeumannU. (2001) Marek's disease virus infection in the brain: virus replication, cellular infiltration, and major histocompatibility complex antigen expression. Vet. Pathol., 38, 491–503.
14.
GimenoI.M. (2008) Marek's disease vaccines: a solution for today but a worry for tomorrow?Vaccine, 18, 31–41.
15.
GoetzE.J., BandaM.J., and LeppertD. (1996) Matrix metalloproteinases in immunity. J. Immunol., 1, 1–4.
16.
HimelsteinB.P., and KochC.J. (1998) Studies of IV collagenase regulation by hypoxia. Cancer Lett., 124, 127–133.
17.
HirayamaK., YokotaH., OnaiR., KobayashiT., KumataT., KiharaK., OkamotoM., SakoT., NakadeT., IzumisawaY., and TaniyamaH. (2002) Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. J. Comp. Pathol., 127, 249–256.
18.
KossakowskaA.E., HuchcroftS.A., UrbanskiS.J., and EdwardsD.R. (1996) Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br. J. Cancer, 73, 1401–1408.
19.
KrugerA., ArltM.J., GergM., KopitzC., BernardoM.M., ChangM., MobasheryS., and FridmanR. (2005) Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res., 1, 3523–3526.
20.
LoukopoulosP., MungallB.A., StrawR.C., ThorntonJ.R., and RobinsonW.F. (2003) Matrix metalloproteinase-2 and -9 involvement in canine tumors. Vet. Pathol., 40, 382–394.
21.
MendesO., KimH.T., LunguG., and StoicaG. (2007) MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin. Exp. Metastasis, 24, 341–351.
22.
Mun-BryceS., and RosenbergG.A. (1998) Matrix metalloproteinases in cerebrovascular disease. J. Cereb. Blood Flow Metab., 18, 1163–1172.
23.
OlkowskiA.A., RathgeberB.M., SawickiG., and ClassenH.L. (2001) Ultrastructural and molecular changes in the left and right ventricular myocardium associated with ascites syndrome in broiler chickens raised at low altitude. J. Vet. Med. A Physiol. Pathol. Clin. Med., 48, 1–14.
24.
OzyigitM.O., KahramanM.M., and SonmezG. (2005) The identification of matrix metalloproteinases and their tissue inhibitors in broiler chickens by immunohistochemistry. Avian Pathol., 34, 509–516.
25.
RathN.C., HuffW.E., BalogJ.M., BayyariG.R., and ReddyR.P. (1997) Matrix metalloproteinase activities in avian tibial dyschondroplasia. Poult. Sci., 76, 501–505.
26.
RathN.C., HuffG.R., BalogJ.M., and HuffW.E. (1998) Fluorescein isothiocyanate staining and characterization of avian heterophils. Vet. Immunol. Immunopathol., 64, 83–95.
27.
RayJ.M., and Stetler-StevensonW.G. (1994) The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur. Respir. J., 7, 2062–2072.
28.
RosenbergG., and NavratilM. (1997) Metalloproteinase inhibition blocks oedema in intracerebral hemorrhage in the rat. Neurology, 48, 921–926.
29.
SeftorR.E., SeftorE.A., De LarcoJ.E., KleinerD.E., LefersonJ., Stetler-StevensonW.G., McNamaraT.F., GolubL.M., and HendrixM.J. (1998) Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exp. Metastasis, 16, 217–225.
30.
SierC.F., KubbenF.J., GaneshS., HeerdingM.M., GriffioenG., HanemaaijerR., van KriekenJ.H., LamersC.B., and VerspagetH.W. (1996) Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer, 74, 413–417.
31.
SorsaT., RamamurthyN.S., VernilloA.T., ZhangX., KonttinenY.T., RifkinB.R., and GolubL.M. (1998) Functional sites of chemically modified tetracyclines: Inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. J. Rheumatol., 25, 975–982.
32.
Stetler-StevensonW.G., HewittR., and CorcoranM. (1996) Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol., 7, 147–154.
33.
Van ThemscheC., AlainT., KossakowskaA.E., UrbanskiS., PotworowskiE.F., and St-PierreY. (2004a) Stromelysin-2 (matrix metalloproteinase 10) is inducible in lymphoma cells and accelerates the growth of lymphoid tumors in vivo. J. Immunol., 15, 3605–3611.
34.
Van ThemscheC., PotworowskiE.F., and St-PierreY. (2004b) Stromelysin-1 (MMP-3) is inducible in T lymphoma cells and accelerates the growth of lymphoid tumors in vivo. Biochem. Biophys. Res. Commun., 19, 884–891.
35.
WebbA.A., and MuirG.D. (2000) The blood-brain barrier and its role in inflammation. J. Vet. Intern. Med., 14, 399–411.
36.
WoessnerJ.F. (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J., 5, 2145–2154.
37.
ZengZ., CohenA.M., and GuillemJ.G. (1999) Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis, 20, 749–755.
